INBRX-106 Adds a Randomized Response Signal in HNSCC
Inhibrx reported primary-endpoint results from the randomized Phase II portion of HexAgon in first-line, treatment-naive, PD-L1 CPS at least 20 metastatic or unresectable recurrent head and neck squamous-cell carcinoma. INBRX-106 plus pembrolizumab produced a…
